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A B S T R A C T
Background: Current understanding of the etiology of autism is based on the interaction of multiple genes with
each other and with environmental factors, leading to a neurodevelopmental process that results in the ex-
pression of autism spectrum disorder (ASD) in the child. This suggests that it might be possible to strengthen
resilience to environmental stressors during the perinatal period to improve outcomes and possibly prevent the
development of ASD.
Methods: We searched the MEDLINE database for multiple perinatal factors associated with the development of
ASD published between January 1, 2005 and July 1, 2018. The search terms used were “autism” crossed with
either “perinatal,” “prenatal,” “gestational,” or “pregnancy,” and crossed again with each perinatal risk factor
highlighted in this review including topics on parental health, infections, medications, and environmental
stressors. We then searched interventions that may improve neurodevelopmental outcome before and during
pregnancy, including supplements, breastfeeding, and postpartum stress reduction. We identiﬁed recent or
unique metanalyses and systematic reviews of the identiﬁed focus and on randomized controlled trials and
summarized these using the most recent and comprehensive reviews.
Results: Folate, omega-3, vitamin D3, environmental toxin avoidance, correcting deﬁciencies, immune boosting,
and prolonged breast feeding are all reported to be linked to the possible reduction of adverse pregnancy out-
comes including ASD.
Conclusions: Studies of individual components for improving pregnancy outcomes and several uncontrolled
preconception to infancy medical practices suggest that multiple interventions might improve the outcomes of
pregnancies where there is risk for developing ASD.
Introduction
Autism Spectrum Disorder (ASD) is characterized by marked im-
pairments in verbal and non-verbal communication combined with
restrictive, repetitive patterns of behavior [1]. The prevalence of ASD
has risen signiﬁcantly since the 1980s from 3.3 cases of pervasive de-
velopmental disorders per 10,000 children. In 1996, the prevalence was
3.4 cases of autism per 1000 children [2]. Using data from 2012, the
Autism and Developmental Disabilities Monitoring (ADDM) Network,
estimated 1 in 68 children were aﬀected [3] and recently, the Centers
for Disease Control and Prevention (CDC) estimated autism prevalence
to be 1 in 59 among the US children, based on an analysis of 2014
medical records and, where available, educational records of 8-year-old
children from 11 monitoring sites [4].
The factors of this rise in prevalence is likely multifactorial. Possible
explanations include 1) diagnostic expansion and substitution, 2) better
reporting, 3) increased recognition, 4) increasing acceptability, and 5)
immigration for services. However, other factors such as infection and
immunity as well as exposure to environmental toxicants and other
environmental factors may also play a role in increasing prevalence.
Although as many as 25% of autism cases have a clear genetic etiology
[5], concordance rates based on twin studies (monozygotic: 0.50–0.77,
dizygotic: 0.31–0.36) support the combination of gene and environ-
ment interaction in the development of ASD [6].
Environmental agents may inﬂuence epigenetic processes through
modiﬁcations of gene expression, rather than changes in the DNA se-
quence itself. Such changes in gene expression can also render some
individuals more susceptible to the eﬀects of certain toxicants [7]. The
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wide range of developmental phenotypes implies a complex and in-
dividualized process. Moreover, the dysregulation of neuronal con-
nectivity by gene by environment (GxE) interactions may be heightened
during critical periods of fetal development [8], suggesting the im-
portance of GxE interactions during pregnancy. Such GxE interaction is
seen at levels of gene expression beginning with histone modiﬁcation
and methylation [9] and may be inﬂuenced by the metabolic processes
such as immune abnormalities/inﬂammation [10]; oxidative stress
[11]; mitochondrial dysfunction [12]; free fatty acid metabolism [13];
and excitatory/inhibitory imbalance [14].
This review supports the possibility that interventions to normalize
or mitigate these processes, particularly in the preconception or peri-
natal period, could lead to resilience and health in the developing and
newborn child [15]. An intriguing retrospective case series of 294
general pediatric patients, many with a sibling on the spectrum, found
that when the pediatrician gave mothers advice during their pregnancy
including minimizing toxicant exposure and acetaminophen use, max-
imizing breast feeding, using probiotics, and limiting antibiotics, no
new cases of autism arose from these families during a 7-year period
[16].
Method
To identify factors associated with the perinatal period and the
development and potential prevention of ASD in the oﬀspring, we
searched the MEDLINE database for studies published between January
1, 2005 and July 1, 2018 for perinatal risk factors and autism ﬁltering
for humans. We then searched for perinatal risk factors such as infec-
tions, medications, and environmental factors including non-chemical
stressors, chemical and nutritional factors. Finally, we searched for
interventions that may improve neurodevelopmental outcome in-
cluding nutritional supplements during pregnancy, breastfeeding, and
postpartum stress reduction. The search terms “autism,” “perinatal,”
“prenatal,” “gestational,” and “pregnancy” were crossed with each risk
factor discussed in this paper. We identiﬁed recent or unique metana-
lyses and systematic reviews of the identiﬁed focus and on randomized
controlled trials and summarized those using the most recent and
comprehensive reviews. Space requirements and focus limit the number
of individual studies included. We report the ﬁndings from the strongest
studies with adequate power, statistical signiﬁcance, and consistency in
replication divided into prenatal, gestational and post-natal inﬂuences
and then review studies of interventions that are associated with im-
proved ASD outcomes. This review will discuss the risk factors for de-
veloping ASD before and during pregnancy. First, we will discuss par-
ental health before conception, then maternal health and
environmental exposures during pregnancy, and conclude with inter-
ventions that can reduce the risk of developing ASD before and during
pregnancy.
Results
Population reviews and meta-analyses
A meta-analysis from 37,634 children with autism and 12,081,416
neurotypical children highlighted numerous prenatal, perinatal and
postnatal factors associated with autism prevalence, including maternal
and paternal age ≥35 years, gestational hypertension, gestational dia-
betes, antepartum hemorrhage, cesarean delivery, gestational age
≤36weeks, induced labor, preeclampsia, fetal distress, low birth
weight, postpartum hemorrhage, male gender, and brain anomaly in
the infant among the factors associated with the development of ASD
[17]. A nest case- control study of Kaiser Permanente records found
children with ASD were more likely to have been exposed to perinatal
(HR=1.15, 95% CI: 1.09–1.21), antepartum (HR=1.22, 95% CI:
1.10–1.36), and intrapartum complications (HR=1.10, 95% CI:
1.04–1.17) than neurotypical children [18]. Furthermore, a study of
8760 children with ASD age matched with 26,280 controls in the
Military Health System database found associations with maternal
epilepsy, obesity, hypertension, diabetes, polycystic ovary syndrome,
infection, asthma, assisted fertility, hyperemesis, younger age, labor
complications, and infant low birth weight, infection, epilepsy, birth
asphyxia and newborn complications [19]. To investigate the link be-
tween perinatal factors and risk of ASD, future studies should consider
risk speciﬁcity for ASD beyond nonspeciﬁc neurodevelopmental risk,
timing of risk and protective mechanisms, and human and animal
models to study mechanisms of gene-environment interactions [20]
(See Table 1).
Parental health before and during pregnancy
Maternal and gestational diabetes and weight gain
Several studies report that pre-gestational and gestational diabetes
mellitus (GDM) in the mother is associated with ASD in the oﬀspring
[21–24]. Pre-gestational diabetes may confer particular risk for ASD
when it co-occurs with maternal obesity [25,26]. Most recently, un-
adjusted average annual ASD incidence rates per 1000 children were
4.4 for exposure to Type 1 diabetes in the mother; 3.6 for Type 2
Diabetes; 2.9 for gestational diabetes by 26weeks; 2.1 for gestational
diabetes after 26 weeks; and 1.8 for no diabetes [27]. A longitudinal
study of 1311 mother-child pairs in the US found increased odds (OR
3.13; 95% CI, 1.10–8.94) of diagnoses of developmental delay and ASD
in children of mothers who were simply obese [28], after adjusting for
potential causal factors.
Proposed mechanisms for the association between maternal dia-
betes, obesity and ASD include increased fetal oxidative stress and in
utero inﬂammatory processes [29,21]. The relationships between glu-
cose control, timing of gestational diabetes, and oﬀspring ASD seems an
important area for ASD risk and should be a subject of future study.
Birth spacing
ASD was associated with both inter-pregnancy interval (IPI) of less
than 18months (aOR 1.5 [1.1–2.2]) and greater than 60months (1.5
[0.99–2.4]). Both short and long IPI associations were stronger among
ASD cases with high severity scores (aORs 2.0 [1.3–3.3] and 1.8
[0.99–3.2], respectively) [30].
Maternal autoimmune and inﬂammatory disorders
Altered immune responses are reported among persons with ASD
and their parents. A Swedish study of 1227 children with ASD and 25
matched controls for each case (30,693 controls with parent data)
Table 1
ASD Perinatal Risk Factors and Possible Preventive Interventions.
Risk Factors Interventions
Maternal & Gestational Diabetes Glucose control, ? < oxidative stress, ?Tx
< inﬂammation
Weight Gain Diet, Exercise
Birth Spacing > 18 <60months
Autoimmune & Inﬂammatory
Disorders
Tx autoimmune d/o and inﬂammation
Advanced Parental Age ? programs to improve immunity and
heath
Maternal infection & Fever Reduce fever; ?antibiotics/antipyretics
Air pollution Limit exposure; > immune
Environmental Chemicals Limit exposure; > immune
Medications Consider strongest studies & risk: beneﬁt
for use
Labor & delivery complications Prenatal, labor & delivery skilled care
Postpartum Depression & Stress Vigilance & Apprpriate Intervention
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found parental autoimmune disorders, particularly maternal type I
diabetes, idiopathic thrombocytopenic purpura, myasthenia gravis, and
rheumatic fever, were weakly but signiﬁcantly associated with oﬀ-
spring ASD (maternal OR=1.6, 95% CI: 1.1–2.2; paternal OR=1.4,
95% CI: 1.0–2.0) [31]. An increased risk of ASD is reported in children
born to mothers with a history of celiac disease [32], rheumatoid ar-
thritis [33] and systemic lupus erythematous (SLE) [34].
Anti-fetal brain autoantibody (Ab+) is shown to be present in 25%
of 227 mothers of children with ASD in the Childhood Autism Risk from
Genetics and the Environment (CHARGE) study [35]. This study
showed that, of mothers of children with severe ASD, those with either
type 2 or gestational diabetes were 2.7 times more likely to be Ab+
compared to healthy mothers (95% CI 1.1–6.6) [35].
The role of dysregulation between the mother’s and infant’s immune
system as a risk factor for autism is currently an important area of in-
vestigation [36]. A systematic review and meta- analysis found sig-
niﬁcant associations between maternal autoimmune diseases developed
during pregnancy or maternal thyroid disease and the risk of ASD in
oﬀspring (pooled OR, 1.30, 1.29, respectively) [37]. Such eﬀect of
maternal autoimmune disorders on neurodevelopment of the oﬀspring
may relate to the inﬂammatory eﬀect of autoantibodies and cytokines,
possibly through vertical transfer, rather than the maternal auto-
immune disorder itself. Increased C-reactive protein (CRP) levels in
mothers during pregnancy was signiﬁcantly associated with autism in
the oﬀspring [38]. Adequately treating autoimmune and inﬂammatory
disorders and preventing ﬂare- ups during pregnancy may reduce
perinatal risk factors for ASD.
Advanced parental age
Advanced maternal age is independently associated with ASD in
several studies, though many of these lack standardized methodologies
and statistical controls for paternal age, parity, birth order, or other
confounding factors [39]. A meta-analysis in 2012 found statistically
signiﬁcant risk in mothers at least 35 years old, with relative risk in-
creasing with rising maternal age [40].
The association between advanced paternal age and autism is in-
creasingly reported [41]. A population-based cohort study of over 2
million individuals born in Sweden between 1973 and 2001 showed a
76% increased risk for ASD in children whose fathers were older than
45 years compared to children of fathers 20–25 years old (HR=1.76,
95% CI= 1.36–2.28) [42]. A meta- analysis of 27 studies found the
highest parental age category was associated with an increased risk of
autism in the oﬀspring, with adjusted ORs 1.41 (95% CI 1.29–1.55) and
1.55 (95% CI 1.39–1.73) for mother and father, respectively [43].
A large cohort study from ﬁve countries involving over 30,000
children with ASD found that advanced paternal and maternal age were
independently associated with increased risk of ASD after adjusting for
the other parent’s age [44].
A focus of future study should be to understand whether the inﬂu-
ence of parental age is through immunity or accumulated toxins or
other mechanisms and if health-related programs to improve these
vulnerabilities might improve outcomes. In addition, pregnancy plan-
ning programs should educate couples in this potential risk.
Maternal infection and fever during pregnancy
A meta-analysis of 15 studies found that maternal infection during
pregnancy was associated with increased ASD risk (OR=1.13, 95% CI:
1.03–1.23) and was likely modulated by type of infectious agent, time
and site of exposure and possibly copy number variants [45]. Maternal
exposure to second-trimester fever among 95,754 children with 583
cases of ASD born in Norway was associated with increased ASD risk,
(adjusted odds ratio (aOR), 1.40; 95% conﬁdence interval, 1.09–1.79),
with a similar, but non-signiﬁcant, point estimate in the ﬁrst trimester.
Risk increased markedly with exposure to three or more fever episodes
after 12 weeks’ gestation (aOR, 3.12; 1.28–7.63) [46].
Maternal congenital cytomegalovirus (CMV) infection and sub-
sequent congenital CMV are associated with ASD [47], but too few
reported events impose limits on generalizability and further studies are
needed [47].
It is uncertain whether the eﬀect of inﬂuenza is due to the virus
itself, the body’s immune response to it, or the eﬀect of antibiotics/
antipyretics use. To address this, a case-controlled study from the
CHARGE study collected exposure information and found that while
neither ASD nor developmental delays were associated with inﬂuenza
during pregnancy, both were associated with maternal fever during
pregnancy. Furthermore, fever-associated ASD risk was reduced among
mothers who took antipyretic medications [48]. This suggests the as-
sociation may be related to induction of inﬂammatory mediators rather
than the viral illness itself. Additionally, low C- reactive protein during
pregnancy has been associated with oﬀspring ASD, suggesting a pos-
sible immune dysregulation that contributes to ASD [49].
Environmental risk factors during pregnancy
Environmental factors associated with ASD include air pollution,
various neurotoxic and endocrine-disrupting pesticides, valproic acid,
thalidomide, mercury, and misoprostol. Other chemicals such as poly-
chlorinated biphenyls, toluene, lead, methylmercury, and arsenic also
are implicated in developmental neurotoxicity [50].
Air pollution
Air pollution, consisting of hazardous air toxicants, particulate
matter, ozone, nitrous oxide, and automobile exhaust-related pollution,
is consistently associated with ASD during all trimesters of pregnancy in
population-based case-control studies [51,52]. While a systematic re-
view and meta-analysis of over 1000 references concluded that evi-
dence of the association of air pollutants and risk of ASD was limited,
the strongest evidence was for the association between prenatal ex-
posure to particulate matter and ASD [53]. Two recent studies ex-
amined daily concentrations of particulate matter from air pollution
monitors and found perinatal exposure to particulate matter increased
ASD risk [54,55]. Nevertheless, low socioeconomic status is associated
with maternal obesity and diabetes, lower education, and higher ex-
posure to air pollution, all of which may be confounding risk factors for
the ASD [56].
An epigenetic mechanism for neurodevelopmental toxicity asso-
ciated with air pollution is suggested by a study showing that particu-
late matter (PM2.5) induced signiﬁcant redox imbalance, DNA hypo- or
hypermethylation, and a bnormal mRNA expression of autism candi-
date genes in neuronal cells [57]. The ﬁne particles can induce oxida-
tive stress, dysfunction in microglia, and ultimately neuroinﬂammation
[58]. These preliminary studies again suggest that aberrant immune
response may play a major role in poorer neurodevelopmental out-
comes associated with air pollution.
Environmental chemicals
Insecticides are commonly designed to damage neurotransmission
[59]. Maternal exposure to one of the most commonly used class of
insecticides, organophosphate pesticides, measured by its urinary me-
tabolite dialkylphosphate (DAP) levels during pregnancy was asso-
ciated with increased risk of PDD in two-year olds from Latino farm-
worker families [60]. From the CHARGE case-control study, proximity
of the mother during pregnancy to organophosphate pesticide appli-
cation was associated with a 60% increase in odds of ASD. Particular
risk was conferred during the 2nd trimester (OR=3.3; 95% CI: 1.5,
7.4) and 3rd trimester (OR=2.0; 95% CI: 1.1, 3.6). The same study
also found pyrethroids insecticide application just before conception or
in the third trimester increased risk. However, a recent study found an
J. Cheng, et al. Medical Hypotheses 127 (2019) 26–33
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increased risk of ASD among girls (OR for a doubling in the DMTP
concentration: 1.64 (95%CI, 0.95; 2.82)) but not among boys (OR: 0.84,
95%CI: 0.63; 1.11) [61]. These ﬁndings suggest windows of vulner-
ability and gender diﬀerences that require further investigation.
Organochlorine compounds (OCs), including organochlorine
pesticides (OCPs) and polychlorinated biphenyls (PCBs), are organic
pollutants, of which many have been banned in the United States since
the 1970s. However, OCs are lipophilic and bioaccumulate in the food
chain because of their long half-life, thus levels are still measurable in
human blood today [62,63].
Matched controlled pairs from the Finnish Prenatal Study of Autism
found the odds of autism among oﬀspring are signiﬁcantly increased
with maternal p,p′-DDE (metabolite of DDT) levels that were in the
highest 75th percentile (odds ratio= 1.32, 95% CI=1.02, 1.71) while
the odds of autism with intellectual disability were increased by greater
than twofold (odds ratio= 2.21, 95% CI= 1.32, 3.69) [64].
Phthalates are widely used in cosmetics, plastics, carpets, ﬂooring,
toys, and medical and cleaning products, and can disturb hormones
critical for brain development [65]. Prenatal exposure to phthalates is
shown to be associated with social, communicative, and cognitive
deﬁcits, as well as with ASD in studies of several hundred participants
[66–68].
Heavy metals such as lead and mercury are well-established tox-
icants of the developing nervous system, where high levels are asso-
ciated with loss of cognitive functioning and behavioral problems [69].
Pregnant mothers living close to industrial facilities releasing lead,
mercury, and arsenic, have increased oﬀspring ASD risk [68,70]. An
analysis of tooth-matrix biomarkers from twins discordant for autism,
found that siblings who developed autism had higher levels of lead and
lower levels of essential nutrients manganese and zinc during the pre-
natal period and ﬁrst 5 months postnatally [71].
A comprehensive review of 91 studies focusing on the association of
mercury and ASD found that 74% suggest mercury as a risk factor for
ASD [72]. The authors concluded that mercury has both a direct and
indirect eﬀect on neuronal damage by causing oxidative stress, auto-
immune activation, neuroinﬂammation and neuronal damage, which
then correlate with ASD symptoms [71]. However, a large population
study found no adverse eﬀect of total prenatal blood Hg levels on di-
agnosed autism (AOR 0.89; 95% CI 0.65, 1.22) per standard deviation
of Hg (P=0.485) [73]. The CHARGE study cohort measured newborn
bloodspot mercury concentrations and maternal reports of ﬁsh con-
sumption during pregnancy and found no association between gesta-
tional methylmercury exposure, primarily from seafood consumption,
and ASD risk (OR=0.95, 95% CI: 0.95, 1.12) [74]. Although subject to
memory bias, this study was the ﬁrst to address prenatal cumulative
methylmercury exposure and autism.
Medications and substance abuse during pregnancy
A review of prescription data, psychiatric registers, and birth re-
cords from 655,615 Danish children, found increased ASD risk in the
508 children who were exposed to valproic acid in utero, with a ha-
zard ratio of 2.9 (95% CI: 1.4–6.0) [75]. With its signiﬁcant teratogenic
eﬀects, maximum precautions should be taken to avoid valproic acid
during pregnancy [76].
Thalidomide, used to ease morning sickness and help sleep, is a
teratogen that has been associated with phocomelia and other devel-
opmental disorders. Hence it was banned for use during pregnancy but
historically is associated with an increased incidence of autism [21].
Selective serotonin reuptake inhibitors (SSRIs) during preg-
nancy cross the placenta and are secreted in breast milk [21], exposing
both the fetus and infant. Reports of elevated blood serotonin levels in
patients with ASD suggest a possible association between prenatal SSRI
exposure and ASD [77], although studies diﬀer on which trimester
shows the strongest association [78–82]. Two systematic reviews and
meta-analyses concluded that prenatal SSRI exposure is associated with
increased risk of ASD, though maternal psychiatric condition as a
confounding factor could not be ruled out [76,83,84]. However, a meta-
analysis of 4 case-control studies and 2 cohort studies concluded that
the association between ﬁrst trimester maternal exposure to SSRI and
child autism was unclear, even after adjusting for maternal mental ill-
ness [85]. Health registry studies found no association between ma-
ternal use of SSRIs and oﬀspring ASD after controlling for confounding
factors such as a direct eﬀect of aﬀective disorder [21]. Further in-
vestigations of these associations with large sample sizes and study of
maternal mental health surrounding pregnancy are needed.
Acetaminophen (paracetamol) use during gestation may be asso-
ciated with problems in neurodevelopment and possibly ASD. In a
Spanish birth cohort of 2644 mother-child pairs, children exposed to
acetaminophen in utero had more ASD symptoms in males and atten-
tion- related problems in both sexes [86]. A meta-analysis of seven
studies found increased risk for ASD (Risk Ratio= 1.23, 95% CI
1.13,1.32, I2+ 17% [87].
A link between alcohol exposure in utero and occurrence of ASD
was ﬁrst reported in the 1990s [21]. However, a large population-based
cohort study found no positive associations between ASD and average
alcohol consumption or number of binge drinking episodes during
pregnancy [88].
Labor and delivery risk factors
Children with ASD are more likely to have complications around the
time of delivery [18]. These include premature birth [89,90], long
duration of delivery and acute fetal distress [91], and birth asphyxia
and preeclampsia [18]. Cesarean section (CS) is signiﬁcantly associated
with an increased odds for ASD (OR: 1.26, 95% CI: 1.22–1.30) after
adjusting for gestational age, site, maternal age and birth year [89].
This association may be inﬂuenced by the other complications during
delivery that cause fetal stress, such as prematurity, prolonged labor,
birth asphyxia, and others, which can necessitate emergency CS. Aug-
mentation of labor with oxytocin is found to be modestly associated
with an increased risk for autism in males (HR 1.13; 95% CI, 1.00–1.26;
P= 0.04) in a sample of 557,040 children in Denmark [90], but the
connection has not been conﬁrmed.
Interventions that may improve neurodevelopmental outcome
Folate and folinic acid
The CHARGE study found that mothers of children with ASD had
lower folic acid intake than mothers of typically developing children,
and a mean daily folic acid intake of ≥600 μg was associated with
reduced ASD risk [91]. Another recent study found increased odds of
oﬀspring ASD with low maternal folic acid intake (< 800 μg) and in-
door pesticide exposure during pregnancy [92]. A meta-analysis of 12
articles with 16 studies consisting of 4514 cases found that supple-
mentation with folic acid during pregnancy could reduce the risk of
ASD [RR=0.771, 95% CI= 0.641–0.928, I2=59.7%,
Pheterogeneity = 0.001]. In addition, when folate receptor autoantibodies
(FRAA) in the serum of 40 children with ASD and 42 gender and age
matched children with typical development, serum FRAA were present
in 77.5% (31/40) of children with ASDs compared with 54.8% (23/42)
of TD children (P=003746, Fischer’s exact test)[93]. Further, among
mothers with high folate intake (> 800 μg) in the ﬁrst trimester, ex-
posure to increasing levels of all air pollutants, except ozone, was as-
sociated with decreased ASD risk, while increased ASD risk was ob-
served for the same pollutant among mothers with low folate intake
(≤800 μg). The diﬀerence was statistically signiﬁcant for NO2 (e.g.,
NO2 and low FA intake: OR=1.53 (0.91, 2.56) vs NO2 and high FA
intake: OR=0.74 (0.46, 1.19), P-interaction=0.04) [94] (See
Table 2).
Studies imply that more folate is not necessarily better. Although
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maternal multivitamin supplementation of 3–5 times per week was
associated with lower risk of ASD, high levels of maternal B12
(> 600 pmol/L) and folate (> 59 nmol/L) were associated with in-
creased risk of ASD [95]. In fact, the highest risk was found in mothers
who had both excess folate and B12. Thus, there may be an optimal
level of folate during pregnancy for reducing the oﬀspring ASD risk
[94].
Omega-3 polyunsaturated fatty acid
A negative correlation between polyunsaturated fatty acids (PUFA)
consumption and development of psychiatric disorders is reported [96],
but the relationship between consumption during pregnancy and ASD is
less clear. Of the PUFAs, omega-3 PUFAs, found mostly in ﬁsh, have
been associated with decreased risk of ASD, while omega-6 PUFAs
contained in vegetable oils and grains, are shown to have harmful ef-
fects [97,98]. However, other studies have yielded diﬀerent results. In
one study, mothers in the highest quintile of total PUFA and omega-6
fatty acid intake showed 34% reduction in risk of having a child with
ASD, but no decrease in risk was associated with higher intake of
omega-3. This may be due to the limited variability in the intake of
these speciﬁc fatty acids and high correlation among the various dietary
fatty acids in the study population [99].
PUFAs’ protective mechanism remains unclear, but studies have
linked a three- to four- fold increase in ASD in males to their negligible
ability to convert a fatty acid precursor into docosahexaenoic acid
(DHA), a particularly neuroprotective agent. Such metabolic advantage
in females may be important for meeting the demands of fetal brain
development during pregnancy, which requires an adequate supply of
long chain-PUFAs [100]. These results suggest that omega-3 supple-
mentation during pregnancy and lactation may confer some protection
against ASD and should be strongly considered as pre- and perinatal
supplements [95] but in need of additional clinical trials.
Vitamin D
Lower 25-hydroxyvitamin D (25(OH)D) levels at 18 weeks and
13.5 weeks gestation is associated with more language, mental, and
psychomotor diﬃculties in the oﬀspring at ages 5 and 10 [101,102]. A
follow-up study found no diﬀerence in 25(OH)D level at 18 weeks ge-
station among mothers of children with and without ASD (n=929)
[103]. However, confounders such as socioeconomic status and low
response rate in the follow-up study make generalizability diﬃcult
[104].
A recent study of over 4000 mothers found that those with gesta-
tional vitamin D deﬁciency (25(OH)D < 25 nmol) had children with
worse Social Responsiveness Scale scores at 6 years [105]. A registry-
based population study of over 500,000 mothers found an association
between lifetime diagnosis of maternal vitamin D deﬁciency and ASD
with intellectual disability, but not without intellectual disability, in the
oﬀspring (OR 2.52, 95% CI 1.22–5.16) [106]. Further supporting this, a
study examining ﬁrst trimester maternal serum vitamin D status found
lower levels of 25(OH)D associated with increased risk of oﬀspring ASD
[107].
An open label trial of vitamin D for mothers with at least one child
with ASD examined the eﬀect of 5000 IU of vitamin D daily during
pregnancy (n=19) and either 7000 IU during breastfeeding or 1000 IU
for newborn infants in the ﬁrst three years of life if they did not
breastfeed [108]. Despite being a small study, they found that recur-
rence rate of autism in newborn siblings was 5% compared to levels of
up to 20% reported in the literature. Since this study had no controls or
blinding, it is promising but preliminary and supports further in-
vestigation.
Multivitamin and nutritional supplementation
A prospective cohort study of more than 200,000 mother-child pairs
found lowered prevalence of ASD with intellectual disability in children
born to mothers who reported multivitamin (MV) supplementation
during pregnancy, compared to mothers who reported no MV, iron, or
folic acid supplementation (OR: 0.69, 95% CI: 0.57–0.84) [109].
However, maternal MV use was not associated with ASD without in-
tellectual disability in the same study [108]. A recent systematic review
of prenatal nutrients and childhood mental illness assessed randomized
trials of folic acid, phosphatidylcholine and omega-3 fatty acid along
with reports of Vitamins A and D and concluded that prenatal nutrients
should be considered as “uniquely eﬀective ﬁrst steps in decreasing risk
for future psychiatric and other illnesses in newborn children” [110].
Iodine and thyroid interventions
The presence of the maternal anti-thyroid peroxidase antibody
during gestation is associated with verbal, perceptive, cognitive and
motor disturbances, as well as almost 80% increase in the odds of
having an oﬀspring with autism (OR=1.78, 95% CI=1.16–2.75,
p=0.009) [111]. Therefore, checking for maternal anti-thyroid per-
oxidase may be valuable for determining potential ASD risk factors in
the future.
Iron
A CHARGE study examined maternal iron intake and risk of ASD in
the children. Findings showed that the highest iron intake was asso-
ciated with reduced ASD risk, especially during breastfeeding [112]. In
addition, low iron intake interacts with advanced maternal age and
metabolic conditions, conferring a 5-fold increase in ASD risk [111].
Therefore, appropriate iron status and treatment of anemia during
pregnancy is likely important for decreasing children’s risk of ASD.
Choline/phosphatidylcholine
A recent double-blind placebo-controlled trial of oral phosphati-
dylcholine supplementation during pregnancy resulted in fewer atten-
tion problems and less social withdrawal in the treated group (N=23)
compared to placebo at 40months of age, by parent ratings [113].
Although observational evidence of the beneﬁts of choline during
pregnancy for neurological health of the child exists, a systematic re-
view concluded that interventional studies are insuﬃcient [114].
Postpartum factors that may improve outcome
Breastfeeding
Breastfeeding, through the transference of oxytocin in breast milk, is
shown to contribute to social recognition, social bonding, and neuro-
development in the infant [115,116]. Maternal levels of oxytocin in-
crease during lactation to reduce stress, protecting mothers from
Table 2
Evidence for Interventions that may Improve Neurodevelopmental
Outcomes.
Agent Evidence*
Folic and Folinic Acid Grade B; Moderate Certainty
Omega-3 PUFA Grade B; Moderate Certainty
Vitamin D Grade B; Moderate Certainty
Multivitamins Grade B; Moderate Certainty
Iron Grade C; Moderate Certainty
Choline Grade C; Low
Breastfeeding Grade B; Moderate
* U.S. Preventive Services Task Force Quality Rating Criteria https://
www.ncbi.nlm.nih.gov/books/NBK47515/.
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anxiety while breastfeeding [117]. Numerous studies support oxytocin’s
role in maternal attachment and enhancing social development in the
infant [118]. Therefore, oxytocin may be able to reduce stress for the
mother and encourage social bonding in the newborn, perhaps helping
to reduce risk of autism [118]. The potential therapeutic application of
oxytocin is promising, and a more consistent dose, administration
method, duration, and objective measurements in future research may
reveal its potential protective eﬀects.
Breastfeeding also transfers long-chain PUFAs. Breastfed infants or
those born to mothers with PUFA intake from ﬁsh greater than 2–3
times per week during pregnancy score better on development scales
(Bayley Scales of Infant Development) and mental scores (McCarthy
Scales of Children’s abilities) than non-breastfed or low duration
breastfed infants [119,120].
Although the exact mechanism is unknown, sub-optimal breast-
feeding is associated with risk of ASD, as well as other behavioral and
cognitive deﬁcits [121–123]. Thus, clinicians should educate parents
about the medical and neurodevelopmental beneﬁts of breastfeeding
and encourage breastfeeding to minimize the risk of ASD in the child.
Postpartum depression and stress
Postpartum depression is common and occurs in 10–22% of mothers
[124]. Although psychotropic drugs are generally considered safe to use
postpartum [123], studies on the relationship between maternal use of
antidepressants during pregnancy and development of ASD in children
are inconclusive [125]. Future studies on the interplay between post-
partum stress/depression, psychotropic use, and oxytocin levels, and
risk of ASD are needed.
Discussion and summary
The search for the etiology of ASD is challenging due to inﬂuences
from multiple domains of genetic and environmental factors. However,
there is evidence that certain intervention during pregnancy may im-
prove outcomes. These are the standards of care, such as quality and
consistent perinatal care from skilled providers, nutritional diet, ex-
ercise, avoiding toxic exposures and breast feeding. Others suggested by
this literature review are that we might be able to aﬀect processes in-
volved in epigenetic inﬂuences that improve resilience and neurode-
velopment such as those that improve or impair inﬂammatory and
immune processes, oxidative stress, mitochondrial health and free fatty
acid metabolism.
Disorders associated with inﬂammation such as maternal diabetes,
obesity, and autoimmune disorders are consistently associated with the
risk for autism in the child, suggesting the critical role of the immune
system to respond to environmental stressors that may lead to epige-
netic changes. Chemical toxins in the environment are less clearly as-
sociated, but perinatal exposure to air pollution and its association with
autism is strongly suggested. Other chemicals such as various pesti-
cides, polychlorinated biphenyls, bisphenols, and phthalates have also
been implicated but have been less frequently studied.
Valproic acid and thalidomide have consistently shown toxic eﬀects
on neurodevelopment. Perinatal SSRI exposure and association with
autism is weak. Studies of acetaminophen’s possible link to autism raise
concerns because it is a pregnancy category B medication widely ac-
cepted for use during pregnancy.
Although environmental stressors and toxicants raise the risk for the
development of autism, several hopeful interventions exist to improve
resilience and neurodevelopmental outcome. One of the most studied is
folate supplementation, which may have an optimal dose to prevent
harm from over-supplementation. Supplementation with omega-3 and
with vitamin D3 has support for a beneﬁcial eﬀect. Iodine and thyroid
deﬁciencies, despite their uncertain direct associations with ASD, are
harmful to neurodevelopment, and levels should be monitored and
managed during pregnancy. Likewise, iron levels should be monitored
and deﬁciencies supplemented. Because of concerns about toxicants
and ASD, consumers might look for phlatates in the product labels,
most commonly diethyl phthalate (DEP), di-n-butyl phthalate (DnBP),
and di-isobutyl phthalate (DiBP), to prevent exposure to these chemi-
cals [126]. Finally, postnatal factors such as breastfeeding and reducing
postpartum stress may enhance the role of oxytocin in social develop-
ment and help improve social bonding with the child.
Designing a strong study to support the usefulness of these inter-
ventions in reducing the number of new cases with neurodevelopmental
disorders such as ASD would involve a large population where risk
factors and interventions could be controlled prospectively, ﬁdelity
assessed, and outcomes reliably measured. Several countries around the
world could do such a study. One small uncontrolled study described
earlier [16] supports the idea that perinatal interventions support im-
proved outcome odds. In the meantime, parents and their providers
might consider the perinatal risk factors and preventive strategies de-
scribed in this review to possibly improve neurodevelopmental out-
comes of oﬀspring during the perinatal period.
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